ALL libraries (COBIB.SI union bibliographic/catalogue database)
  • Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer [Elektronski vir] : a systematic review
    Strojan, Primož ...
    Background. The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for non-metastatic head and neck squamous cell carcinoma (HNSCC) has ... not been determined. Methods. The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols vs. radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for non-nasopharyngeal HNSCC was extracted. In the case of non-randomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results. Eleven randomized trials and 7 non-randomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p=0.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion. Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.
    Source: Head & neck [Elektronski vir]. - ISSN 1097-0347 (Vol. 28, iss. 1, 2016, str. E2151-E2158)
    Type of material - e-article
    Publish date - 2016
    Language - english
    COBISS.SI-ID - 2010491
    DOI

Shelf entry